Company | Cap $ | P/E | P/B | P/S | ROE | ROA | ROS | L/A | P/FCF | PR | Period |
---|---|---|---|---|---|---|---|---|---|---|---|
Outset Medical | 185 | 2023q3 | |||||||||
Affimed | 434 | 2021 | |||||||||
RemeGen Co. | 1,191 | 2023 | |||||||||
Alector | 436 | 2023q2 | |||||||||
ContextLogic | 123 | 2023q3 | |||||||||
Adaptive Biotechnologies | 621 | 2023q3 | |||||||||
Sangamo Therapeutics | 91 | 2023q3 | |||||||||
Greenlane Holdings | 2 | 2023q2 | |||||||||
Sunrun | 4,633 | 2023 | |||||||||
Apartment Investment and... | 896 | 2023q3 | |||||||||
Fidelity National Informa... | 41,743 | 2022 | |||||||||
Blend Labs | 1,102 | 2023q3 | |||||||||
UroGen Pharma | 382 | 2023q2 | |||||||||
Aytu BioPharma | 10 | 2022 | |||||||||
Burning Rock Biotech | 774 | 2024q1 | |||||||||
MicroStrategy | 6,194 | 2023q3 | |||||||||
EHang Holdings | 1,150 | 2024q2 | |||||||||
Alnylam Pharmaceuticals | 33,795 | 2022 | |||||||||
Axsome Therapeutics | 3,872 | 2024q2 | |||||||||
Karyopharm Therapeutics | 104 | 2022 |